Rennova Health, Inc.

Overview

• IndustryServices-General Medical & Surgical Hospitals, NEC²
• HeadquartersSan Francisco, United States²
• Incorporated inDE³
• Business address400 S. Australian Avenue, Suite 800, West Palm Beach, Fl 33401³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI5493004XX4UYHW85FP41²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 2545851²

See how the biggest companies compare on our leaderboards

Health, Inc. is the result of a merger between two public companies, Medytox Solutions, Inc. and CollabRx, Inc. Medytox Solutions, Inc.⁵ From its latest annual report

Corporate structure

Rennova Health, Inc. sits at the top of its group. 17 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC. Each entity in the chart links to its source.

What it owns

What Rennova Health, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

The table below summarizes certain information as to our principal facilities:

Location · Purpose · Type of Occupancy

Item 2 of the 10-K filed Feb 14, 2025.⁵

Leadership

Who has led Rennova Health, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerSeamus Lagan Nov 16, 2015 to Jul 25, 2018¹⁴
• Chief executive officerJames Karis Jul 12, 2012 to Jul 12, 2012¹⁵
• Chief executive officerChristine Terese Hergenrother Nov 18, 2009 to Nov 18, 2009¹⁶
• Chief executive officerThomas Mika Nov 22, 2006 to Jan 7, 2015¹⁷
• PresidentSeamus Lagan Nov 16, 2015 to Jul 25, 2018¹⁴
• PresidentThomas Mika Nov 22, 2006 to Jan 7, 2015¹⁷
• Chief financial officerJonathan Immordino Apr 15, 2019 to Apr 15, 2019¹⁸
• Chief financial officerMarlene McLennan Jul 3, 2018 to Jul 3, 2018¹⁹
• Chief financial officerMichael H. Pollack May 24, 2017 to May 24, 2017²⁰
• Chief financial officerJason Adams Nov 12, 2015 to Jul 27, 2016²¹
• Chief financial officerJames Karis Jul 12, 2012 to Jul 12, 2012²²
• Chief financial officerChristine Terese Hergenrother Jan 4, 2006 to Jul 1, 2011²³
• Chief operating officerSamuel R. Mitchell Jr. Nov 12, 2015 to Nov 12, 2015²⁴
• Chief operating officerClifford Joseph Baron Mar 12, 2014 to Nov 30, 2015²⁵

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• Alethea Laboratories, Inc. Texas⁴
• Biohealth Medical Laboratory, Inc. Florida⁴
• CarePlus Medical, Inc. Kentucky⁴
• EPIC Reference Labs, Inc. Florida⁴
• Epinex Diagnostics Laboratories, Inc. California⁴
• International Technologies, LLC New Jersey⁴
• Jamestown TN Medical Center, Inc. Tennessee⁴
• Jellico Medical Center, Inc. Tennessee⁴
• Medical Billing Choices, Inc. North Carolina⁴
• Medytox Diagnostics, Inc. Florida⁴
• Medytox Institute of Laboratory Medicine, Inc. Florida⁴
• Medytox Solutions, Inc. Nevada⁴
• Mountain View Physician Practice, Inc. Tennessee⁴
• PB Laboratories, LLC Florida⁴
• Platinum Financial Solutions, LLC Florida⁴
• Rennova Health Services TN, Inc. Tennessee⁴

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• CollabRx, Inc.Aug 3, 2012 to Oct 28, 2015³
• TEGAL CORP /DE/Feb 14, 1996 to Sep 25, 2012³

Timeline

1. Nov 8, 20248-K Other events⁴⁷
2. Sep 20, 20248-K Entered a material agreement; Completed an acquisition or sale⁴⁸
3. Jun 17, 20248-K Entered a material agreement; Regulation FD disclosure; Other events⁴⁹
4. Mar 26, 20248-K Entered a material agreement⁵⁰
5. Oct 31, 20238-K Entered a material agreement⁵¹
6. Aug 21, 20238-K Regulation FD disclosure⁵²
7. Apr 24, 20238-K Regulation FD disclosure⁵³
8. Feb 23, 20238-K Regulation FD disclosure⁵⁴
9. Nov 23, 20228-K Other events⁵⁵
10. Oct 20, 20228-K Regulation FD disclosure⁵⁶
11. Sep 23, 20228-K Other events⁵⁷
12. Sep 14, 20228-K Regulation FD disclosure⁵⁸
13. Nov 16, 2015New chief executive Seamus Lagan becomes CEO¹⁴
14. Jul 12, 2012New chief executive James Karis becomes CEO¹⁵
15. Nov 18, 2009New chief executive Christine Terese Hergenrother becomes CEO¹⁶
16. Nov 22, 2006New chief executive Thomas Mika becomes CEO¹⁷
17. Sep 20, 1995Founded Rennova Health, Inc. is founded²

Filings

55 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 23 major events, 5 private raises, 17 other. The latest 20:

1. Feb 14, 202510-K EDGAR
2. Nov 8, 20248-K EDGAR
3. Sep 20, 20248-K EDGAR
4. Jun 17, 20248-K EDGAR
5. May 16, 2024NT 10-Q EDGAR
6. Apr 1, 2024NT 10-K EDGAR
7. Mar 26, 2024424B3 EDGAR
8. Mar 26, 20248-K EDGAR
9. Jan 11, 2024424B3 EDGAR
10. Nov 14, 202310-Q EDGAR
11. Oct 31, 20238-K EDGAR
12. Aug 21, 20238-K EDGAR
13. Aug 15, 202310-Q EDGAR
14. Aug 15, 2023NT 10-Q EDGAR
15. May 16, 2023424B3 EDGAR
16. May 15, 202310-Q EDGAR
17. May 12, 2023EFFECT EDGAR
18. May 11, 2023CORRESP EDGAR
19. May 9, 2023S-1/A EDGAR
20. Apr 24, 20238-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Mar 11, 2022Raised $1.5 million in a private offering of equity Form D: 2 investors so far Form D
2. Oct 28, 2021Raised $4 million in a private offering of equity Form D: 2 investors so far Form D
3. Sep 8, 2021Raised $1 million in a private offering of equity Form D: 2 investors so far Form D

SEC filer profile

How Rennova Health, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARRennova Health, Inc.¹
• CIK0000931059
• Employer ID (EIN)68-0370244⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)8062 Services-General Medical & Surgical Hospitals, NEC¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address400 S. Australian Avenue, Suite 800, West Palm Beach, FL 33401¹
• Phone561-855-1626¹
• Shares outstanding43,051,322,257 shares as of Feb 4, 2025⁵
• Public float$3.0M as of Jun 30, 2023⁵
• AuditorHaynie & Company, Salt Lake City, Utah PCAOB ID 457; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceFeb 14, 1996¹
• Filings1,258 in all: 8-K (319), 4 (264), 10-Q (83), CORRESP (54), 3 (45), D (37), SC 13D/A (28), 10-K (27)¹
  All 58 form types

  SC 13G/A (27), UPLOAD (27), DEF 14A (26), 4/A (24), S-1/A (23), SC 13G (21), 10-K/A (16), SC 13D (14), 425 (13), PRE 14A (12), S-3 (12), S-3/A (12), S-8 (12), 8-K/A (11), EFFECT (11), NT 10-Q (11), 5 (10), NT 10-K (9), PRE 14C (9), S-1 (9), 424B3 (8), DEF 14C (8), 10-Q/A (7), FWP (7), D/A (6), DEFA14A (6), 424B4 (4), PRER14A (4), REGDEX (4), 424B5 (3), 8-A12B (3), POS AM (3), S-8 POS (3), 10-K405 (2), 10-K405/A (2), 25-NSE (2), 424B2 (2), CERTNAS (2), DEFR14A (2), RW (2), S-4/A (2), SC TO-I/A (2), 3/A (1), AW (1), POS EX (1), PREM14A (1), S-1MEF (1), S-2 (1), S-4 (1), SC 13E3 (1)

• Latest filingsAnnual report (10-K) Feb 14, 2025
  Quarterly report (10-Q) Nov 14, 2023
  Proxy statement (DEF 14A) Mar 14, 2018
  Latest 8-K (8-K) Nov 8, 2024

Risk factors and legal proceedings

The risks Rennova Health, Inc. names in Item 1A of its 10-K filed Feb 14, 2025: 38 risks under these headings, as written.⁵

• The Company’s operations have historically operated at a loss and with a cash deficiency. The Company has limited access to capital and is dependent on its ability to secure the funding required for its cash requirements and to execute on its business plan. Unless we raise sufficient funds, we will not be able to execute our business model.
• Although our financial statements have been prepared on a going concern basis, we have accumulated significant losses and have had negative cash flows from operations that could adversely affect our ability to refinance existing indebtedness or raise additional capital to fund our operations or limit our ability to react to changes in the economy or our industry, which raise substantial doubt about our ability to continue as a going concern.
• Our behavioral health facility may not become profitable.
• Our holding company structure makes us dependent on our subsidiaries for our cash flow and could serve to subordinate the rights of our shareholders to the rights of creditors of our subsidiaries, in the event of an insolvency or liquidation of any such subsidiary.
• The Company sold several of its subsidiaries to InnovaQor, Inc. (“InnovaQor”) and has a convertible preferred stock investment in and note receivable with InnovaQor. An inability to monetize its convertible preferred stock investment and/or receive cash proceeds in connection with repayment of the note receivable could have a material adverse effect on the Company.
• The Company sold several of its subsidiaries to FOXO and has a convertible preferred stock investment in and notes receivable with FOXO and its subsidiaries. An inability to monetize its convertible preferred stock investment and/or receive cash proceeds in connection with repayments of the notes receivable could have a material adverse effect on the Company.
• Our business has substantial indebtedness; certain of our debt instruments are in payment default and/or repayment of a related party loan has been requested. In addition, several of our debt instruments contain restrictive covenants, which may affect our operational and financial flexibility.
• We may have a limited ability to use some or all of our net operating loss carryforwards in the future.
• Our results of operations may be adversely affected if the Patient Protection and Affordable Care Act (“ACA”) is repealed, replaced or otherwise changed.
• General economic conditions.
• Healthcare plans have taken steps to control the utilization and reimbursement of healthcare services.
• Some of our operations are subject to federal and state laws prohibiting “kickbacks” and other laws designed to prohibit payments for referrals and eliminate healthcare fraud.

Legal proceedings

From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

The opening of Item 3, Legal Proceedings.⁵